Results 11 to 20 of about 3,722,377 (405)
Driving Immune Responses in the Ovarian Tumor Microenvironment
Frontiers in Oncology, 2021 Ovarian cancer is the leading cause of death among gynecological neoplasms, with an estimated 14,000 deaths in 2019. First-line treatment options center around a taxane and platinum-based chemotherapy regimen. However, many patients often have recurrence
Franklin Ning, C. B. Cole, C. Annunziata
semanticscholar +1 more source
Cancers, 2020 We aimed to develop a diagnostic model identifying ovarian cancer (OC) from benign ovarian tumors using metagenomic data from serum microbe-derived extracellular vesicles (EVs). We obtained serum samples from 166 patients with pathologically confirmed OC
S. I. Kim +10 more
semanticscholar +1 more source
Journal for ImmunoTherapy of Cancer, 2020 Background Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT).
Joao M Santos +11 more
semanticscholar +1 more source
Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy
Cancers, 2022 Simple Summary Ovarian cancer is a highly lethal female malignancy with high rates of advanced stage and recurrent disease. Ovarian cancer is characterized as poorly responsive to immunotherapy.
D. Schweer +5 more
semanticscholar +1 more source
Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model.
Small, 2020 Virus-like nanoparticles (VLPs) have been used as an attractive means in cancer immunotherapy because of their unique intrinsic immunostimulatory properties.
Chao Wang +7 more
semanticscholar +1 more source
Biodegradable Mg Implants Suppress the Growth of Ovarian Tumor.
ACS Biomaterials Science & Engineering, 2020 The common treatment of epithelial ovarian cancer is aggressive surgery followed by platinum-based cytotoxic chemotherapy. However, residual tumor cells are resistant to chemotherapeutic drugs during postoperative recurrence.
S. Qiao +10 more
semanticscholar +1 more source
Primary ovarian carcinoid arising in associated mature cystic teratoma
BMC Women's Health, 2022 Background Primary ovarian carcinoid is a very rare ovarian low-grade neuroendocrine tumor, accounting for about 0.1% of all ovarian neoplasms. Case presentation We reported a case of primary ovarian carcinoid arising from a mature cystic teratoma in a ...
Wanyu Zhang, Qiongrong Chen
doaj +1 more source
HER2/Neu Expression was Different between Benign, Borderline and Malignant Epithelial Ovarian Tumors
Indonesian Journal of Obstetrics and Gynecology, 2014 Objective: To determine the difference of HER2/neu expression in benign, borderline and malignant epithelial ovarian tumor. Method: An analytic cross-sectional study was performed on 49 samples of epithelial ovarian cases which were divided into three
Yona S. Hadisubroto, Ketut Suwiyoga
doaj +1 more source
Exosomes promote pre-metastatic niche formation in ovarian cancer. [PDF]
, 2019 Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Dean, Dylan C +4 more
core +2 more sources
HE4 in the differential diagnosis of ovarian masses [PDF]
, 2015 Ovarian masses, a common finding among pre- and post-menopausal women, can be benign or malignant. Ovarian cancer is the leading cause of death from gynecologic malignancy among women living in industrialized countries.
ANASTASI, Emanuela +5 more
core +1 more source